Table 9

Number of administrations for each product
Agent Induction year Maintenance year 5 year total
Adalimumab 27 26 131
Etanercept 64 52 272
Infliximab 8 7 36
Ustekinumab 5 4 22

Avgerinou et al.

Avgerinou et al. BMC Dermatology 2012 12:10   doi:10.1186/1471-5945-12-10

Open Data